The role of Toll-like receptors in chronic B cell malignancies

References

• Muzio M, Mantovani A. Toll-like receptors. Microbes Infect 2000; 2: 251–255
   PubMed Web of Science ®Google Scholar
• Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311: 1–16
   PubMed Web of Science ®Google Scholar
• Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect 2004; 6: 1382–1387
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol 2007; 19: 268–274
   PubMed Web of Science ®Google Scholar
• Muzio M, Ni J, Feng P, Dixit V M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278: 1612–1615
   PubMed Web of Science ®Google Scholar
• Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998; 187: 2097–2101
   PubMed Web of Science ®Google Scholar
• Akira S. Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 2000; 28: 551–556
   PubMed Web of Science ®Google Scholar
• Muzio M, Mantovani A. Toll-like receptors (TLRs) signalling and expression pattern. J Endotoxin Res 2001; 7: 297–300
   PubMedGoogle Scholar
• Leadbetter E A, Rifkin I R, Hohlbaum A M, Beaudette B C, Shlomchik M J, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603–607
   PubMed Web of Science ®Google Scholar
• Ehlers M, Fukuyama H, McGaha T L, Aderem A, Ravetch J V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006; 203: 553–561
   PubMed Web of Science ®Google Scholar
• Lau C M, Broughton C, Tabor A S, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202: 1171–1177
   PubMed Web of Science ®Google Scholar
• Inohara, Chamaillard, McDonald C, Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005; 74: 355–383
   PubMed Web of Science ®Google Scholar
• Fritz J H, Ferrero R L, Philpott D J, Girardin S E. Nod-like proteins in immunity, inflammation and disease. Nat Immunol 2006; 7: 1250–1257
   PubMed Web of Science ®Google Scholar
• Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004; 101: 3522–3526
   PubMed Web of Science ®Google Scholar
• Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003; 4: 920–927
   PubMed Web of Science ®Google Scholar
• Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9: 143–150
   PubMed Web of Science ®Google Scholar
• O'Neill L A. SIGIRR puts the brakes on Toll-like receptors. Nat Immunol 2003; 4: 823–824
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Barton G M. Toll-like receptor pathway. Sci Signal, 2009, Available at: http://stke.sciencemag.org/cgi/cm/stkecm;CMP_8643. Accessed 23 August 2005
   Google Scholar
• Bernasconi N L, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101: 4500–4504
   PubMed Web of Science ®Google Scholar
• Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003; 102: 956–963
   PubMed Web of Science ®Google Scholar
• Ruprecht C R, Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 2006; 36: 810–816
   PubMed Web of Science ®Google Scholar
• Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531–4537
   PubMed Web of Science ®Google Scholar
• Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol 2005; 174: 2942–2950
   PubMed Web of Science ®Google Scholar
• Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol 2008; 20: 420–425
   PubMed Web of Science ®Google Scholar
• Wagner M, Poeck H, Jahrsdoerfer B, et al. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 2004; 172: 954–963
   PubMed Web of Science ®Google Scholar
• Miura Y, Shimazu R, Miyake K, et al. RP105 is associated with MD-1 and transmits an activation signal in human B cells. Blood 1998; 92: 2815–2822
   PubMed Web of Science ®Google Scholar
• Gavin A L, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314: 1936–1938
   PubMed Web of Science ®Google Scholar
• Meyer-Bahlburg A, Rawlings D J. B cell autonomous TLR signaling and autoimmunity. Autoimmun Rev 2008; 7: 313–316
   PubMed Web of Science ®Google Scholar
• Isnardi I, Ng Y S, Srdanovic I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008; 29: 746–757
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Manz R A. Tolls for B cells. Eur J Immunol 2006; 36: 798–801
   PubMed Web of Science ®Google Scholar
• Bekeredjian-Ding I, Inamura S, Giese T, et al. Staphylococcus aureus protein A triggers T cell-independent B cell proliferation by sensitizing B cells for TLR2 ligands. J Immunol 2007; 178: 2803–2812
   PubMed Web of Science ®Google Scholar
• Poeck H, Wagner M, Battiany J, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004; 103: 3058–3064
   PubMed Web of Science ®Google Scholar
• Huggins J, Pellegrin T, Felgar R E, et al. CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood 2007; 109: 1611–1619
   PubMed Web of Science ®Google Scholar
• Jiang W, Lederman M M, Harding C V, Rodriguez B, Mohner R J, Sieg S F. TLR9 stimulation drives naive B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007; 37: 2205–2213
   PubMed Web of Science ®Google Scholar
• Bernasconi N L, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199–2202
   PubMed Web of Science ®Google Scholar
• Gauld S B, Dal Porto J M, Cambier J C. B cell antigen receptor signaling: roles in cell development and disease. Science 2002; 296: 1641–1642
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 2004; 18: 1711–1716
   PubMed Web of Science ®Google Scholar
• Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004; 100: 107–115
   PubMed Web of Science ®Google Scholar
• Ferreri A J, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007; 63: 245–256
   PubMed Web of Science ®Google Scholar
• Cavalli F, Isaacson P G, Gascoyne R D, Zucca E. MALT Lymphomas. Hematology Am Soc Hematol Educ Program 2001; 241–258
   PubMedGoogle Scholar
• Forman D, Webb P, Parsonnet J. H pylori and gastric cancer. Lancet 1994; 343: 243–244
   PubMed Web of Science ®Google Scholar
• Hussell T, Isaacson P G, Crabtree J E, S J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122–127
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Isaacson P G. Bacterial infection and MALT lymphoma. N Engl J Med 2004; 350: 213–215
   PubMed Web of Science ®Google Scholar
• Zucca E, Bertoni F, Roggero E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998; 338: 804–810
   PubMed Web of Science ®Google Scholar
• Purdue M P, Lan Q, Wang S S, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009; 30: 275–281
   PubMed Web of Science ®Google Scholar
• Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor α and lymphoma risk. Genes Immun 2006; 7: 615–624
   PubMed Web of Science ®Google Scholar
• Forrest M S, Skibola C F, Lightfoot T J, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006; 134: 180–183
   PubMed Web of Science ®Google Scholar
• Hellmig S, Fischbach W, Goebeler-Kolve M E, Folsch U R, Hampe J, Schreiber S. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2005; 46: 869–872
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia 2006; 20: 937–938
   PubMed Web of Science ®Google Scholar
• Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. PAMP are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20: 1130–1137
   PubMed Web of Science ®Google Scholar
• Bohnhorst J, Rasmussen T, Moen S H, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20: 1138–1144
   PubMed Web of Science ®Google Scholar
• Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G. TLR3 ligand induces NF-{κ}B activation and various fates of multiple myeloma cells depending on IFN-{α} production. J Immunol 2009; 182: 4471–4478
   PubMed Web of Science ®Google Scholar
• Hamblin T. Is chronic lymphocytic leukemia a response to infectious agents?. Leuk Res 2006; 30: 1063–1064
   PubMed Web of Science ®Google Scholar
• Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113: 1008–1016
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003; 21: 841–894
   PubMed Web of Science ®Google Scholar
• Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111: 3838–3848
   PubMed Web of Science ®Google Scholar
• Stevenson F K, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103: 4389–4395
   PubMed Web of Science ®Google Scholar
• Ghia P, Caligaris-Cappio F. The origin of B-cell chronic lymphocytic leukemia. Semin Oncol 2006; 33: 150–156
   PubMed Web of Science ®Google Scholar
• Messmer B T, Albesiano E, Efremov D G, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200: 519–525
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109: 259–270
   PubMed Web of Science ®Google Scholar
• Belessi C J, Davi F B, Stamatopoulos K E, et al. IGHV gene insertions and deletions in chronic lymphocytic leukemia: “CLL-biased” deletions in a subset of cases with stereotyped receptors. Eur J Immunol 2006; 36: 1963–1974
   PubMed Web of Science ®Google Scholar
• Spaner D E, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 2007; 21: 53–60
   PubMed Web of Science ®Google Scholar
• Grandjenette C, Kennel A, Faure G C, Bene M C, Feugier P. Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells. Haematologica 2007; 92: 1279–1281
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio M T, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll-like receptors in chronic lymphocytic leukaemia cells. Br J Haematol 2009; 144: 507–516
   PubMed Web of Science ®Google Scholar
• Longo P G, Laurenti L, Gobessi S, et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110–120
   PubMed Web of Science ®Google Scholar
• Porakishvili N, Kulikova N, Jewell A P, et al. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005; 131: 313–319
   PubMed Web of Science ®Google Scholar
• Decker T, Peschel C. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells. Leuk Lymphoma 2001; 42: 301–307
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Muhlenhoff L, Blackwell S E, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005; 11: 1490–1499
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Wooldridge J E, Blackwell S E, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leuk Biol 2005; 77: 378–387
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Blackwell S, Weiner G. The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility. Leukemia 2007; 21: 2354–2355, author reply 2355–2356
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558–568
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999–1006
   PubMed Web of Science ®Google Scholar
• Shi Y, White D, He L, Miller R L, Spaner D E. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007; 67: 1823–1831
   PubMed Web of Science ®Google Scholar
• Spaner D E, Shi Y, White D, et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 2006; 20: 286–295
   PubMed Web of Science ®Google Scholar
• Decker T, Hipp S, Kreitman R J, Pastan I, Peschel C, Licht T. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood 2002; 99: 1320–1326
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81–88
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002; 16: 327–334
   PubMed Web of Science ®Google Scholar
• Castro J E, Prada C E, Aguillon R A, et al. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 2006; 20: 680–688
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002; 32: 1403–1413
   PubMed Web of Science ®Google Scholar
• Granziero L, Circosta P, Scielzo C, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood 2003; 101: 1962–1969
   PubMed Web of Science ®Google Scholar
• Ghia P, Circosta P, Scielzo C, et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005; 294: 135–145
   PubMed Web of Science ®Google Scholar
• Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777–2783
   PubMed Web of Science ®Google Scholar